| Autor: |
Atsuhi Yanase, Toru Sugihara, Takahiro Akimoto, Hirotaka Yokoyama, Jun Kamei, Akira Fujisaki, Satoshi Ando, Tameto Naoi, Mitsuya Morita, Tetsuya Fujimura |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
IJU Case Reports, Vol 5, Iss 4, Pp 251-254 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2577-171X |
| DOI: |
10.1002/iju5.12447 |
| Popis: |
Introduction We report a prostate cancer case diagnosed during leuprorelin treatment for spinal and bulbar muscular atrophy which is a X‐linked recessive, lower motor neuron disease. Case presentation A 64‐year‐old man who had received leuprorelin treatment over 3 years for his spinal and bulbar muscular atrophy presented with an enlarged prostate accompanied by abdominal pain and constipation. An abnormally high serum prostate‐specific antigen of 17.7 ng/mL and a low (castration level) serum testosterone level of 0.23 ng/mL were measured. Prostate needle biopsy revealed adenocarcinoma of the prostate. Orchiectomy, darolutamide, and radiation therapy for the prostate were initiated, resulting in a favorable response which was maintained at 12 months of treatment. Conclusion Prostate cancer can occur even when leuprorelin is used for spinal and bulbar muscular atrophy; therefore, checking serum prostate‐specific antigen to screen for prostate cancer before leuprorelin administration should be considered. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text